Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Feb;24(2):89-90.
doi: 10.1080/14728222.2020.1723080. Epub 2020 Feb 3.

ONECUT2 is a novel target for treatment of castration-resistant prostate cancer

Tejashree Joglekar  1   2 , Jianqing Lin  2   3 , Maho Shibata  1   2
Affiliations
Editorial

ONECUT2 is a novel target for treatment of castration-resistant prostate cancer

Tejashree Joglekar et al. Expert Opin Ther Targets. 2020 Feb.
No abstract available

Keywords: AR-independent prostate cancer; ONECUT2; castration-resistant prostate cancer; neuroendocrine prostate cancer; prostate cancer.

PubMed Disclaimer

References

    1. Rotinen M, You S, Yang J, et al. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat Med. 2018. December;24(12):1887–1898.

      ** In this key paper, ONECUT2 was identified as a master transcriptional regulator of mCRPC that could be inhibited by the small molecular inhibitor CSRM617.

    1. Guo H, Ci X, Ahmed M, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019. January 17;10(1):278.

      ** This paper identifies ONECUT2 as a master transcriptional regulator of neuroendocrine prostate cancer and shows that ONECUT2 activation leads to tumor hypoxia.

    1. Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016. March;22(3):298–305. - PMC - PubMed
    1. Zou M, Toivanen R, Mitrofanova A, et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. 2017. July;7(7):736–749. - PMC - PubMed
    1. Lapuk AV, Wu C, Wyatt AW, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012. July;227(3):286–97. - PMC - PubMed

Publication types

MeSH terms